A multicenter study of the immunogenicity and safety of GSK [GlaxoSmithKline] Biologicals' inactivated hepatitis A vaccine (Havrix) administered concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine (Prevnar) in healthy children 15 mths [months] of age.

Trial Profile

A multicenter study of the immunogenicity and safety of GSK [GlaxoSmithKline] Biologicals' inactivated hepatitis A vaccine (Havrix) administered concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine (Prevnar) in healthy children 15 mths [months] of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Hepatitis A; Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Apr 2012 Actual patient number is 521 according to ClinicalTrials.gov.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top